These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 30499732)

  • 81. [Long-acting reversible contraception methods in women under 26 years of age].
    Frutos-Balibrea I; Sánchez-Núñez MI; Pedrero-Pérez EJ; Haro-León A; Benítez-Robredo MT
    Semergen; 2021 Oct; 47(7):457-464. PubMed ID: 34148782
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Current evidence of contraceptive uptake, pregnancy and continuation rates in young women: a systematic review and Meta-analysis.
    Farah D; Andrade TRM; Di Bella ZIKJ; Girão MJBC; Fonseca MCM
    Eur J Contracept Reprod Health Care; 2020 Dec; 25(6):492-501. PubMed ID: 33140990
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Use of long-acting reversible contraceptives in the UK from 2004 to 2010: analysis using The Health Improvement Network Database.
    Cea Soriano L; Wallander MA; Andersson S; Filonenko A; García Rodríguez LA
    Eur J Contracept Reprod Health Care; 2014 Dec; 19(6):439-47. PubMed ID: 25139412
    [TBL] [Abstract][Full Text] [Related]  

  • 84. A three-year comparative study of continuation rates, bleeding patterns and satisfaction in Australian women using a subdermal contraceptive implant or progestogen releasing-intrauterine system.
    Weisberg E; Bateson D; McGeechan K; Mohapatra L
    Eur J Contracept Reprod Health Care; 2014 Feb; 19(1):5-14. PubMed ID: 24229367
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Twelve-month contraceptive continuation among women initiating short- and long-acting reversible contraceptives in North Kivu, Democratic Republic of the Congo.
    Casey SE; Cannon A; Mushagalusa Balikubirhi B; Muyisa JB; Amsalu R; Tsolka M
    PLoS One; 2017; 12(9):e0182744. PubMed ID: 28886016
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Increasing long-acting reversible contraceptives: the Australian Contraceptive ChOice pRoject (ACCORd) cluster randomized trial.
    Mazza D; Watson CJ; Taft A; Lucke J; McGeechan K; Haas M; McNamee K; Peipert JF; Black KI
    Am J Obstet Gynecol; 2020 Apr; 222(4S):S921.e1-S921.e13. PubMed ID: 31837291
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Predictors of contraceptive switching and discontinuation within the first 6 months of use among Highly Effective Reversible Contraceptive Initiative Salt Lake study participants.
    Simmons RG; Sanders JN; Geist C; Gawron L; Myers K; Turok DK
    Am J Obstet Gynecol; 2019 Apr; 220(4):376.e1-376.e12. PubMed ID: 30576664
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Factors Associated with New Uptake of Long-Acting Reversible Contraceptives Since the Affordable Care Act Among Privately Insured Women in Pennsylvania.
    Nelson HN; Thayer E; Bailey C; Leuenberger L; Lehman E; Chuang CH
    Womens Health Issues; 2019; 29(5):370-375. PubMed ID: 31337530
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Prolonged use of the etonogestrel implant and levonorgestrel intrauterine device: 2 years beyond Food and Drug Administration-approved duration.
    McNicholas C; Swor E; Wan L; Peipert JF
    Am J Obstet Gynecol; 2017 Jun; 216(6):586.e1-586.e6. PubMed ID: 28147241
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Uptake and adherence to long-acting reversible contraception post-abortion.
    Rose SB; Lawton BA; Brown SA
    Contraception; 2010 Oct; 82(4):345-53. PubMed ID: 20851228
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Adherence to Recommended Practices for Provision of Long-Acting Reversible Contraception Among Providers in a Large U.S. Health Care System.
    Judge-Golden CP; Wiesenfeld HC; Chen BA; Borrero S
    J Womens Health (Larchmt); 2020 Dec; 29(12):1586-1595. PubMed ID: 32667847
    [No Abstract]   [Full Text] [Related]  

  • 92. Use of contraceptive methods and contraceptive recommendations among health care providers actively involved in contraceptive counseling -- results of an international survey in 10 countries.
    Gemzell-Danielsson K; Cho S; Inki P; Mansour D; Reid R; Bahamondes L
    Contraception; 2012 Dec; 86(6):631-8. PubMed ID: 22770797
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Continuation of copper and levonorgestrel intrauterine devices: a retrospective cohort study.
    Phillips SJ; Hofler LG; Modest AM; Harvey LFB; Wu LH; Hacker MR
    Am J Obstet Gynecol; 2017 Jul; 217(1):57.e1-57.e6. PubMed ID: 28315664
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Chlamydia testing and diagnosis following initiation of long-acting reversible contraception: A retrospective cohort study.
    Rose SB; Garrett SM; Stanley J; Pullon SRH
    Aust N Z J Obstet Gynaecol; 2017 Dec; 57(6):665-675. PubMed ID: 28832936
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Results of a 5-year contraceptive trial in parous and nulliparous women with a new LNG-IUS.
    Wildemeersch D; Goldstuck ND; Jackers G
    Gynecol Endocrinol; 2017 Mar; 33(3):223-226. PubMed ID: 28084114
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Selection and performance of the levonorgestrel-releasing intrauterine system.
    Lähteenmäki P; Bardin CW; Elomaa K; Haukkamaa M; Kivijärvi A; Kuukankorpi A; Venhola M; Tuominen J
    Acta Obstet Gynecol Scand Suppl; 1997; 164():69-74. PubMed ID: 9225643
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Increasing Use of Long-Acting Reversible Contraception to Decrease Unplanned Pregnancy.
    Lotke PS
    Obstet Gynecol Clin North Am; 2015 Dec; 42(4):557-67. PubMed ID: 26598299
    [TBL] [Abstract][Full Text] [Related]  

  • 98. User satisfaction with a levonorgestrel-releasing intrauterine system (LNG-IUS): data from an international survey.
    Römer T; Linsberger D
    Eur J Contracept Reprod Health Care; 2009 Dec; 14(6):391-8. PubMed ID: 19929641
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Comparison of two cohorts of women who expulsed either a copper-intrauterine device or a levonorgestrel-releasing intrauterine system.
    Simonatto P; Bahamondes MV; Fernandes A; Silveira C; Bahamondes L
    J Obstet Gynaecol Res; 2016 May; 42(5):554-9. PubMed ID: 26817571
    [TBL] [Abstract][Full Text] [Related]  

  • 100. A comparative study of the levonorgestrel-releasing intrauterine system Mirena versus the Copper T380A intrauterine device during lactation: breast-feeding performance, infant growth and infant development.
    Shaamash AH; Sayed GH; Hussien MM; Shaaban MM
    Contraception; 2005 Nov; 72(5):346-51. PubMed ID: 16246660
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.